MWM
VRTX icon

Mascoma Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mascoma Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.59K Hold
17
– – ﹤0.01% 341
2025
Q4 		$7.71K Buy
17
+3
+21% +$1.29K ﹤0.01% 338
2025
Q3 		$5.48K Hold
14
– – ﹤0.01% 367
2025
Q2 		$6.23K Hold
14
– – ﹤0.01% 368
2025
Q1 		$6.79K Hold
14
– – ﹤0.01% 371
2024
Q4 		$5.64K Buy
+14
New +$6.49K ﹤0.01% 396

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mascoma Wealth Management's VRTX Position: Q1 2026 in Review

Mascoma Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 17 shares worth $7.59K. The position accounts for ﹤0.01% of the portfolio, ranked #341.

Mascoma Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.71K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mascoma Wealth Management held 17 shares of Vertex Pharmaceuticals worth $7.59K as of Q1 2026.
  • Mascoma Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Mascoma Wealth Management's portfolio in Q1 2026, its #341 holding.
  • Mascoma Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Mascoma Wealth Management's Vertex Pharmaceuticals position peaked at $7.71K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mascoma Wealth Management's 13F filing for Q1 2026, filed 30 Apr 2026.